 After screening, eligible subjects will be randomly assigned to 1 of 2 treatment sequences; CHS-1701 followed by Neulasta Sequence A or Neulasta followed by CHS-1701, Sequence B. Treatments will be spaced by a minimum of 6 weeks apart but no more than 8 weeks. Subjects will be admitted to the Clinical Pharmacology Unit CPU on Day -1 Period 1 and will be confined through Hour 96 postdose a total of approximately 4.5 days and 5 nights. Blood samples will be collected at specified time points postdose for plasma PK and PD measurements and the subjects will be closely monitored for safety. Following discharge on the morning of Day 5 Period 1 subjects will return to the clinic for additional PK, PD and safety follow up--daily through Day 9 and at stated interval time points thereafter. 